Saturday 17 October 2026 Export PLRX’s income statement to Excel — free account

Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022. In the quarter to June 2026, EPS grew 49.3% and free cash flow grew 68.6%, each against the same quarter a year earlier.

0.90 0.07 −7.22%

Follow PLRX

Alert me

Market cap: $60.2M
P/E: 0.0×
Fwd P/E: −1.0×
Dividend yield: —
F-score: 4/9
Altman Z: 15.11
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.16

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	4	—	—	—	—	—	—	—	—	—

Insider Ownership 2.63%

Capital & Financial Ratios $m

Market Cap 60.21

Revenue 5.03

Net Income (92.29)

Free Cash Flow (70.62)

Net Debt (158.10)

Current Ratio 9.90

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.95)

P/S ratio 11.09

P/B ratio 0.38

Past 5Y EPS Growth —

This Y EPS Growth 41.07%

Next Y EPS Growth 5.16%

Next Y revenue growth (13.67%)

Next 5Y EPS Growth 23.86%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 4.15%

10-year low 10-year high

P/B against its own 10 years 6.13%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	494	356	191	158
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	1	1
	506	362	196	163

	2023	2024	2025	Q'26
Payables	5	6	0	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	29	33	16	16

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(66.44%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(8.53%)	(16.69%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’23	1	0	—	—	2
’22	1	5	1	2	10
’21	2	2	2	2	8
’20	29	4	5	4	42

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(13)	—	—	—
’25	(49)	(41)	(21)	(18)	(128)
’24	(30)	(45)	(32)	(48)	(156)
’23	(30)	(25)	(36)	(25)	(116)
’22	(20)	(24)	(18)	(31)	(95)
’21	(14)	(19)	(23)	(20)	(75)
’20	(13)	8	(16)	(16)	(37)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(13)	—	—	—
’25	(49)	(41)	(21)	(18)	(129)
’24	(32)	(47)	(33)	(48)	(159)
’23	(30)	(25)	(36)	(25)	(117)
’22	(21)	(25)	(19)	(31)	(96)
’21	(14)	(20)	(23)	(20)	(77)
’20	(13)	7	(16)	(17)	(39)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.32)	(0.36)	—	—	—
’25	(0.92)	(0.71)	(0.43)	(0.38)	(2.43)
’24	(0.78)	(0.92)	(0.95)	(0.82)	(3.47)
’23	(0.67)	(0.70)	(0.70)	(0.69)	(2.75)
’22	(0.78)	(0.82)	(0.65)	(0.72)	(2.94)
’21	(0.64)	(0.64)	(0.75)	(0.68)	(2.71)
’20	5.81	(1.39)	(0.47)	(0.54)	(1.95)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	19.43	11.91	3.97	12.61	10.22	1.10	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	35.63	43.92	26.25	36.64	19.62	13.71
People
People	Employees	—	—	—	62	78	91	124	158	171	49
	Revenue/emp, $m	—	—	—	0.92	0.54	0.08	0.08	0.01	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	57	42	8	10	2	—	—
	Gross margin, %	—	—	0.00	100.00	100.00	100.00	100.00	100.00	—	—
	EBT	—	—	(30)	(1)	(42)	(97)	(123)	(161)	(210)	(149)
	EBT margin, %	—	—	0.00	(1.11)	(99.32)	(1,284.51)	(1,273.32)	(10,211.14)	0.00	0.00
	Net income	—	0	(30)	(1)	(42)	(97)	(123)	(161)	(210)	(149)
	Depreciation	—	—	1	1	1	3	0	(3)	5	6
Per share, $
Per share, $	Revenue	—	—	0.00	35.14	1.96	0.21	0.23	0.03	0.00	0.00
	Earnings	—	—	(25.98)	(0.39)	(1.95)	(2.71)	(2.94)	(2.75)	(3.47)	(2.43)
	Cash flow	—	—	(24.31)	(1.69)	(1.75)	(2.10)	(2.25)	(1.98)	(2.57)	(2.09)
	Capex	—	—	(1.99)	(0.59)	(0.07)	(0.05)	(0.04)	(0.02)	(0.06)	0.00
	Free cash flow	—	—	(26.30)	(2.29)	(1.82)	(2.16)	(2.29)	(2.00)	(2.63)	(2.09)
	Book value	—	—	52.02	67.75	13.26	5.55	7.46	8.07	5.02	2.95
	Shares, m	—	—	1	2	21	36	42	59	61	61
Valuation, ×
Valuation, ×	P/E	—	—	—	1.39	6.66	0.00	0.00	0.00	—	—
	P/S	—	—	—	0.00	11.60	63.91	82.43	209.79	—	—
	P/B	—	—	—	0.00	1.71	2.43	2.55	2.23	—	—
	EV/Sales	—	—	—	0.00	4.98	38.12	49.26	113.47	—	—
	EV/FCF	—	—	—	17.69	(5.36)	(3.73)	(4.95)	(4.86)	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(28)	(3)	(37)	(75)	(95)	(116)	(156)	(128)
	Capex	—	—	(2)	(1)	(2)	(2)	(2)	(1)	(4)	0
	Free cash flow	—	—	(31)	(4)	(39)	(77)	(96)	(117)	(159)	(129)
Balance, $m
Balance, $m	Working capital	—	—	57	104	279	193	316	477	329	180
	Total debt	—	—	—	—	—	5	10	10	30	—
	Net debt	—	—	(61)	(103)	(277)	(195)	(321)	(484)	(326)	(191)
	Shareholders’ equity	—	—	61	110	283	199	313	474	304	181
Returns, %
Returns, %	ROA	—	—	(105.67)	(7.39)	(20.04)	(37.64)	(43.13)	(37.40)	(46.27)	(48.01)
	ROIC	—	—	0.00	(10.68)	(422.05)	(1,609.28)	0.00	0.00	0.00	0.00
	ROE	—	—	47.58	9.28	(40.17)	(40.35)	(48.13)	(41.00)	(54.09)	(61.55)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Jun 2023

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CING Cingulate Inc.	$63.8M	— (loss-making)	—	—	n/m	−24.28% (below 0%: shrinking)	0.00%	0.00%	Compare
FBIO Fortress Biotech, Inc.	$63.7M	0.6×	1.1×	+14.04% (above 0%: growing)	n/m	−115.37% (below 0%: shrinking)	67.18%	(53.46%)	Compare
APLM Apollomics Inc.	$61.2M	— (loss-making)	—	—	0.00%	+76.08% (above 0%: growing)	—	—	Compare
BMEA Biomea Fusion, Inc.	$60.6M	— (loss-making)	—	—	n/m	+47.80% (above 0%: growing)	0.00%	0.00%	Compare
PLRX Pliant Therapeutics, Inc.	$60.2M	— (loss-making)	— (loss-making)	−95.03% (below 0%: shrinking)	n/m	+68.61% (above 0%: growing)	0.00%	0.00%
XLO Xilio Therapeutics, Inc.	$59.4M	— (loss-making)	— (loss-making)	+131.22% (above 0%: growing)	n/m	−26.23% (below 0%: shrinking)	100.00%	(18.68%)	Compare
GANX Gain Therapeutics, Inc.	$58.1M	— (loss-making)	— (loss-making)	+27.78% (above 0%: growing)	n/m	+8.22% (above 0%: growing)	0.00%	0.00%	Compare
CNTB Connect Biopharma Holdings Limited Sponsored ADR	$57.1M	— (loss-making)	— (loss-making)	+296.56% (above 0%: growing)	n/m	−23.48% (below 0%: shrinking)	100.00%	(635.98%)	Compare
TENX Tenax Therapeutics, Inc.	$56.5M	— (loss-making)	—	−77.98% (below 0%: shrinking)	n/m	−125.93% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$60.0M	—	—	+27.78%	—	−23.88%	0.00%	0.00%

All 614 Biotechnology stocks →

Pliant Therapeutics, Inc. (PLRX) key facts

Concern: Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022.
Pliant Therapeutics, Inc. (PLRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PLRX traded at $0.90, a market capitalization of $60.2 million.
Return on equity was −61.6% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 15.11 (safe zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.